(Q85016673)
Statements
Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial (English)
Dariusz Dudek
Patrick W Serruys
Yoshinobu Onuma
John A Ormiston
Karine Miquel-Hebert
1 January 2012